{"entity":{"id":"egle-therapeutics","kind":"company","name":"Egle Therapeutics","aka":["Egle Therapeutics SAS"],"tldr":"Egle Therapeutics is a Paris company developing medicines that act on regulatory T cells, the immune cells that can shield a tumour from attack. Its cancer drug, EGL-001, is designed to selectively inhibit these cells inside tumours and is in an early trial in advanced solid tumours.","summary":"Egle Therapeutics SAS, based in Paris, develops IL-2 variant immunoconjugates that modulate regulatory T cells (Tregs), using a proprietary discovery platform to find Treg-specific targets. In oncology its lead candidate EGL-001 is a Treg-selective anti-CTLA-4 antibody fused to a modified IL-2 (anti-CTLA4-IL-2m), designed to selectively inhibit Tregs in tumours; in autoimmunity EGL-003 is an IL-2 agonist Treg engager. Christophe Queva was appointed chief executive in January 2025, and the website now names John Celebi as chief executive. Its first registered cancer trial, NCT06622486, a first-in-human phase 1/2 study of EGL-001 in selected advanced or metastatic solid tumours at sites in France and Spain, was posted on ClinicalTrials.gov in October 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.egle-tx.com/"},{"label":"Chief executive appointment, January 2025","url":"https://www.egle-tx.com/egle-therapeutics-strengthens-its-executive-leadership-team-with-the-appointment-of-christophe-queva-ph-d-as-chief-executive-officer/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of EGL-001 (NCT06622486)","url":"https://clinicaltrials.gov/study/NCT06622486"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["immunocytokines"],"targets":["ctla4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06622486"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated in the pages read. No financing round is recorded because no primary source for one was read; the website says only that it is backed by prominent investors. Read on 29 October 2026."],"hq":"Paris","country":"FR","companyType":"biotech","website":"https://www.egle-tx.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/egle-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"immunocytokines","kind":"technology","name":"Immunocytokines (antibody-cytokine fusions)","route":"/technologies/immunocytokines/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"}],"trial":[{"id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/"}]}}